Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation
Our study serves as a pilot study demonstrating that cfDNA methylation biomarkers assessed from a peripheral blood draw can stratify HCC patients into clinically meaningful risk groups. These findings indicate that cfDNA methylation is a promising noninvasive prognostic biomarker for HCC, providing a proof-of-concept for its potential clinical utility and laying the groundwork for broader applications.
Authors
- Vatche G. Agopian (ORCID: https://orcid.org/0000-0003-0130-9838)
- Shuo Li (ORCID: https://orcid.org/0000-0002-1960-6016)
- Ran Hu (ORCID: https://orcid.org/0000-0002-0563-8957)
- Xianghong Jasmine Zhou (ORCID: https://orcid.org/0000-0002-4522-7490)
- Mary L. Stackpole (ORCID: https://orcid.org/0000-0003-4432-6718)
- Yonggang Zhou (ORCID: https://orcid.org/0000-0003-2905-3213)
- Richard S. Finn (ORCID: https://orcid.org/0000-0003-2494-2126)
- Andrew Melehy (ORCID: https://orcid.org/0000-0001-7786-5086)
- Wenyuan Li (ORCID: https://orcid.org/0000-0002-5029-8525)
- Weihua Zeng
- Saeed Sadeghi (ORCID: https://orcid.org/0000-0002-4062-0170)
- Benjamin V. Tran (ORCID: https://orcid.org/0000-0001-8602-5134)
Institutions
- QB3 (US)
- University of California, Los Angeles (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1371/journal.pone.0321736
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Cancer Institute